Abbott and Novo Nordisk collaborate on digital solution for insulin users

Pharmaceutical

Abbott and Novo Nordisk will work together to provide integrated digital solutions that facilitate insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with Abbott’s FreeStyle Libre products, to help diabetics, carers and healthcare professionals view insulin and glucose data together and make informed treatment decisions. The FreeStyle Libre system uses a sensor to read glucose levels rather than the usual finger pricks. It can be worn on the back of the upper arm, and users can capture and view their real-time glucose levels and glucose history on their smartphone.

“Abbott and Novo Nordisk collaborate on digital solution for insulin users.“

Jared Watkin, senior vice president of Diabetes Care, Abbott, said: "It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes. Diabetes is a time-intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake. By enabling insulin dosing data from Novo Nordisk′s connected pens to be shared with our digital health tools, we′ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life."

See all the latest jobs in Pharmaceutical
Return to news